
Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the consensus of $5.84 billion.
The life science giant reported adjusted earnings of $1.80 per share, beating the consensus of $1.64.